Sign up
Pharma Capital

MaxCyte hails US National Institutes of Health tie-up to find treatment for sickle cell disease

The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH
microscope
The pair will use MaxCyte's cell engineering platform

MaxCyte Inc (LON:MXCT) shares rose on Monday after it said it has entered into an R&D agreement with the US National Institutes of Health (NIH) to develop treatments for sickle cell disease. 

They will do so using next-generation CRISPR/Cas9-based single-nucleotide correction technologies enabled by MaxCyte's cell engineering platform.

The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH.

Correcting mutations

The two hope to "correct" the faulty haemoglobin gene that causes the disease and address DNA mutations that contribute to the disease. 

As part of the tie-up, MaxCyte will supply messenger RNA molecules that convey genetic information from DNA to the ribosomes.

It will also use its Flow Electroporation Technology to develop reliable and effective processes to correct gene sequences.

MaxCyte chief executive Doug Doerfler said: "We believe that this work will further validate our platform for developing gene-editing therapies for a broad range of diseases while enabling rapid, development and commercial manufacturing of new therapies for patients where there is an extremely high unmet medical need."

In early morning trading, Maxcyte shares were up 1.6% at 249p.

-- Adds share price --

 

Ian_55ae0ddd437b7.jpg
Why Invest In MaxCyte? Read More Here

Register here to be notified of future MXCT Company articles
View full MXCT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.